China big opportunities
“Now in 2021,” says Peter Lebowitz, global oncology therapeutic area head at J&J’s Janssen, “if we have a target that we like, or a platform that we like, and the team doesn’t bring the Chinese opportunities to me — which they usually do — I’m going to say, we need to see if there’s anything in China, right? And what we find is that those companies in China, when we’re going after something, there are always opportunities in China. Always.”
https://endpts.com/how-china-turned-the-table-on-biopharmas-global-dealmaking/